These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21207666)

  • 1. [The expression of soluble guanylate cyclase in hypoxic and hypercapnic rat lung].
    Xia Xd; Xu ZJ; Bi YT
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2003 May; 19(2):159-60. PubMed ID: 21207666
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.
    Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L
    Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
    Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF
    Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats.
    Reyna-Neyra A; Sarkar G; Etgen AM
    J Neuroendocrinol; 2007 Jun; 19(6):418-25. PubMed ID: 17388815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
    Vermeersch P; Buys E; Pokreisz P; Marsboom G; Ichinose F; Sips P; Pellens M; Gillijns H; Swinnen M; Graveline A; Collen D; Dewerchin M; Brouckaert P; Bloch KD; Janssens S
    Circulation; 2007 Aug; 116(8):936-43. PubMed ID: 17679618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acidic triazoles as soluble guanylate cyclase stimulators.
    Roberts LR; Bradley PA; Bunnage ME; England KS; Fairman D; Fobian YM; Fox DN; Gymer GE; Heasley SE; Molette J; Smith GL; Schmidt MA; Tones MA; Dack KN
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6515-8. PubMed ID: 21924901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NO-independent activators of soluble guanylate cyclase: therapeutic potential.
    Mathew R
    Am J Hypertens; 2009 May; 22(5):470. PubMed ID: 19387430
    [No Abstract]   [Full Text] [Related]  

  • 8. Measurement of cGMP and soluble guanylyl cyclase activity.
    Southam E
    Curr Protoc Toxicol; 2001 May; Chapter 10():Unit 10.5. PubMed ID: 23045027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissues cIMPly do not lie.
    Gao Y; Vanhoutte PM
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Sep; 387(9):901-3. PubMed ID: 25052042
    [No Abstract]   [Full Text] [Related]  

  • 10. Distribution of soluble guanylyl cyclase in rat retina.
    Ding JD; Weinberg RJ
    J Comp Neurol; 2007 May; 502(1):734-45. PubMed ID: 17436468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nitric oxide. Potentiation of NO-dependent activation of soluble guanylate cyclase--(patho)physiological and pharmacotherapeutical significance].
    Severina IS
    Biomed Khim; 2007; 53(4):385-99. PubMed ID: 18035720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Potentiation of NO-dependent activation of soluble guanylate cyclase by polyamines].
    Severina IS; Piatakova NV; Shchegolev AIu
    Biomed Khim; 2007; 53(1):44-9. PubMed ID: 17436683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
    Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
    Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney.
    Bai Y; Ye S; Mortazavi R; Campese V; Vaziri ND
    Am J Physiol Renal Physiol; 2007 Mar; 292(3):F974-80. PubMed ID: 17122386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxic Vasospasm Mediated by cIMP: When Soluble Guanylyl Cyclase Turns Bad.
    Gao Y; Chen Z; Leung SW; Vanhoutte PM
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):545-8. PubMed ID: 25264755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.
    Schäfer A; Flierl U; Kobsar A; Eigenthaler M; Ertl G; Bauersachs J
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2813-8. PubMed ID: 17023677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
    Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
    Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
    Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage.
    Benz K; Orth SR; Simonaviciene A; Linz W; Schindler U; Rütten H; Amann K
    Kidney Blood Press Res; 2007; 30(4):224-33. PubMed ID: 17575468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase: an old therapeutic target re-visited.
    Hobbs AJ
    Br J Pharmacol; 2002 Jul; 136(5):637-40. PubMed ID: 12086972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.